Streetwise Reports' Article Archives — Current Month (27)
Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth (06/20/2026)
Explore Rezolute Inc.'s progress with Ersodetug for hyperinsulinism, including ENDO 2026 data, analyst ratings, and sector trends for retail investors seeking biotech opportunities.
Traws Pharma Positions Long-Acting Antivirals for Influenza and Outbreak Threats as Sector Opportunities Expand (06/20/2026)
Explore Traws Pharma's strategy in respiratory antivirals, cash runway to 2027, pipeline backups, and analyst perspectives amid evolving biopharma funding and flu market needs for retail investors.
Sernova Biotherapeutics leverages its Cell Pouch technology and recent FDA orphan drug designation to address type 1 and type 3c diabetes amid a growing global market, supported by improved financial stability for retail investors.
Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program (06/19/2026)
Traws Pharma, Inc.'s (TRAW:NASDAQ) bird flu antiviral hits a U.K. regulatory hurdle, delaying its Phase 2a study and prompting an analyst downgrade from Buy to Neutral.
Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data (06/19/2026)
Rezolute Inc. (RZLT:NASDAQ) presented promising data at ENDO 2026, with analysts eyeing big gains and a "Buy" rating as Phase 3 study results loom in the second half of 2026.
Biotech Secures Major FDA Orphan Drug Designation for Diabetes Treatment (06/18/2026)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) announces it has been granted orphan drug designation for autologous islet transplantation (AIT) for preventing diabetes following a total pancreatectomy.
enGene Therapeutics Positions Detalimogene for NMIBC Opportunity Amid Expanding Oncology Landscape (06/18/2026)
Explore how enGene Therapeutics is advancing its novel gene therapy, Detalimogene, for bladder cancer within a growing oncology market, including clinical progress, financial strength, and upcoming catalysts for investors.
Teva Pharmaceutical Advances Neuroscience Pipeline With Strong AUSTEDO Growth and New Acquisition (06/17/2026)
Teva Pharmaceutical Industries reports robust first-quarter revenue growth from AUSTEDO and specialty products while closing the Emalex acquisition and advancing multiple late-stage programs in neuroscience, immunology, and respiratory diseases for retail investors.
Oncology BioPharma Co. Reports Mixed Trial Data, Plots Path to FDA (06/17/2026)
enGene Therapeutics Inc. (ENGN:NASDAQ) shared Q2 results and LEGEND trial updates for detalimogene, its non-muscle invasive bladder cancer therapy, as analysts waver on stock.
A New Pharma Giant Goes Public as a Sector Leader Makes Moves in Neuroscience (06/16/2026)
Apotex Health Corp. (APTX:TSX) raised approximately CA$1.3 billion in its IPO while Teva Pharmaceutical Industries Ltd. (TEVA:NYSE) reported new AUSTEDO data and added a late-stage Tourette syndrome asset.
Nuvalent Acquisition by GSK Highlights Growing Opportunities in Targeted Oncology Therapies (06/16/2026)
Explore how the pending GSK acquisition of Nuvalent at a premium underscores sector momentum in precision oncology, with key pipeline catalysts and market trends for retail investors to consider.
Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal (06/15/2026)
Analysts downgrade Nuvalent Inc (NUVL:NASDAQ) to "Neutral" after GSK's US$10.6B all-cash buyout offer at US$124/share, calling the deal favorable but a competing bid unlikely.
MindBio Therapeutics Positions Voice AI Kiosks for Growth in Workplace Safety Markets (06/13/2026)
MindBio Therapeutics advances prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, targeting high-growth opportunities in mining, aviation, and construction sectors amid expanding biotech and AI markets.
Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment (06/13/2026)
Oculis Holding AG launches the PREDICT-1 trial for licaminlimab, targeting patients with a specific TNFR1 genotype to address unmet needs in the large dry eye disease market.
MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors (06/12/2026)
Explore how MindBio Therapeutics is advancing voice-based AI detection for intoxication across mining, aviation, and other industries, backed by strong market trends and analyst targets.
MindBio Therapeutics Advances AI Voice Tech for Workplace Safety in Growing Biotech and AI Detector Markets (06/12/2026)
MindBio Therapeutics delivers first prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, positioning the company in high-growth sectors including mining, aviation, and construction, while analysts highlight significant upside potential.
Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results (06/12/2026)
Oculis Holding AG (OCS:NASDAQ; OCS:XICE) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients.
Biotech Firm Launches Massive AI Safety Solution for Zero-Tolerance Industries (06/11/2026)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) delivers first Edge AI intoxication detection kiosk prototypes for mining, aviation, and construction safety screening.
Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity (06/10/2026)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) launches Intox AI, detecting intoxication via voice, targeting mining and aviation in a US$2.06B market.
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market (06/10/2026)
Explore how ORIC Pharmaceuticals is advancing its oncology pipeline with key catalysts ahead, amid rising global demand for innovative cancer treatments and strong analyst support.
Grey Matters Health Positions for Growth in Expanding Alzheimer's Diagnostics Market (06/10/2026)
Grey Matters Health advances its Alzheimer's neuroimaging strategy with fresh financing and plans for the first U.S. brain-specific PET clinic, capitalizing on rising demand for early detection tools.
Alzheimer's Diagnostic Clinic Initiative Moves Forward After Financing Close (06/09/2026)
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) closed the first CA$500,000 tranche of a financing that the company said will support its Alzheimer's disease program and planned U.S. brain-specific neuroimaging clinic.
Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth (06/08/2026)
ORIC Pharmaceuticals Inc. (ORIC:NASDAQ) granted 34,800 stock options and 5,900 restricted stock units to new employees as analysts issue "Buy" ratings for the year ahead.
Cancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline Progresses (06/05/2026)
Rakovina Therapeutics (TSX.V: RKV) reported lower net losses, reduced administrative spending, debt restructuring, financing activity, and progress across its AI-driven oncology pipeline in Q1 2026.
From Healthcare IT Vendor to AI-Driven Holding Company (06/05/2026)
Healthcare Triangle Inc.'s (HCTI:NASDAQ) Spanish AI acquisition delivers US$34M in revenue and a near-US$40M agentic AI run rate, while shares still trade at just 1x cash.
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% (06/04/2026)
Revolution Medicines Inc.'s (RVMD:NASDAQ) daraxonrasib treats pancreatic cancer patients, doubling median survival. Analysts rate it a "Buy" with targets up to US$263.
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug (06/01/2026)
Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60.
More Archives
2025Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
